Chemoresistance and Stem Cell Selection

Summary

Principal Investigator: David A Williams
Abstract: The success of the gene therapy trial in treatment of severe combined immunodeficiency (SCID) provides evidence of the power and utility of in vivo selection of transduced hematopoietic cell populations. Over the past decade, we and others have demonstrated the effectiveness of a combined gene transfer and pharmacologic approach for in vivo selection of hematopoietic stem cells utilizing chemotherapy-resistance genes. In particular, transfer of mutants of O6 methylguanine DNA methyltransferase (MGMT) in combination with inhibitors of this protein, such as 6-benzylguanine (6-BG), and treatment with alkylating agents have been demonstrated to be highly effective for in vivo selection of hematopoietic cells, specifically hematopoietic stem cells. Gene transfer of MGMT has wide application, not only in stem cell selection, but also in generating chemo-resistant hematopoiesis that may allow dose intensification in cancer therapies. While this approach is effective, little is known neither about the potential damage to the functional stem cell compartment nor the long term effects of residual DNA damage present in long-lived cells after such selection. In addition, although the risk of insertional mutagenesis resulting from integrating retroviruses has received wide-spread recent attention and is an important issue facing application of gene transfer to human diseases, we believe that these risks are related not simply to the integration event, but are likely also dependent upon the specific transgene expressed and other factors involving the manipulated cells, such as proliferative stress and proliferative history. In this interactive, multi-investigator grant application, we propose to examine the effectiveness of in vivo stem cell selection, the effects of such selection on long-term stem cell function, the quantity and quality of residual DNA damage that is present after in vivo selection and finally the pathophysiological relevance of the combination of these factors in addition to vector integration on the incidence of leukemia transformation of hematopoietic cells in vivo. The proposed work includes collaborative efforts of a number of accomplished and productive investigators with expertise in hematopoiesis, virus vector design, detection and characterization of DNA damage and vector integration identification/bioinformatics. The research plan directly models and evaluates the effects of in vivo selection and DNA damage on a critical, sensitive, and therapeutically relevant biological compartment (hematopoietic stem cells). The results from these studies will provide powerful insight into the application of virus vectors to genetic diseases and cancer as well as detailed consequences and benefits of protecting hematopoietic stem cells from DNA damage.
Funding Period: ----------------2006 - ---------------2010-
more information: NIH RePORT

Top Publications

  1. ncbi Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials
    Elke Will
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Mol Ther 15:782-91. 2007
  2. pmc Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection
    Michael D Milsom
    Cincinnati Children s Research Foundation, Cincinnati Children s Hospital Medical Center, Division of Experimental Hematology, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    DNA Repair (Amst) 6:1210-21. 2007
  3. pmc Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression
    Claudia R Ball
    National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
    Blood 110:1779-87. 2007
  4. ncbi Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells
    Lars U W Müller
    Division of Experimental Hematology, Cincinnati Children s Research Foundation, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Mol Ther 16:1154-60. 2008
  5. ncbi Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells
    Michael D Milsom
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Cancer Res 68:6171-80. 2008
  6. pmc Upping the ante: recent advances in direct reprogramming
    Lars U W Müller
    Department of Medicine, Division of Pediatric Hematology Oncology, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Mol Ther 17:947-53. 2009
  7. pmc Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia
    Lars U W Müller
    Department of Medicine, Division of Pediatric Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States
    Mutat Res 668:141-9. 2009
  8. pmc Overcoming reprogramming resistance of Fanconi anemia cells
    Lars U W Müller
    Division of Pediatric Hematology Oncology, Children s Hospital Boston, and Dana Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 119:5449-57. 2012

Detail Information

Publications8

  1. ncbi Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials
    Elke Will
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Mol Ther 15:782-91. 2007
    ....
  2. pmc Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection
    Michael D Milsom
    Cincinnati Children s Research Foundation, Cincinnati Children s Hospital Medical Center, Division of Experimental Hematology, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    DNA Repair (Amst) 6:1210-21. 2007
    ....
  3. pmc Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression
    Claudia R Ball
    National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
    Blood 110:1779-87. 2007
    ....
  4. ncbi Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells
    Lars U W Müller
    Division of Experimental Hematology, Cincinnati Children s Research Foundation, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Mol Ther 16:1154-60. 2008
    ..Collectively, these data support the use of rapid lentiviral transduction for gene therapy in FA...
  5. ncbi Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells
    Michael D Milsom
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Cancer Res 68:6171-80. 2008
    ..These studies have direct translational relevance to ongoing clinical gene therapy studies using MGMT(P140K), whereas the novel mechanistic findings are relevant to the basic understanding of DNA repair by MGMT...
  6. pmc Upping the ante: recent advances in direct reprogramming
    Lars U W Müller
    Department of Medicine, Division of Pediatric Hematology Oncology, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Mol Ther 17:947-53. 2009
    ..We also highlight recent advances that eliminate stable genetic modification from the reprogramming process, and summarize preclinical models that provide proof-of-concept for ES/iPS cell-based regenerative medicine...
  7. pmc Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia
    Lars U W Müller
    Department of Medicine, Division of Pediatric Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States
    Mutat Res 668:141-9. 2009
    ....
  8. pmc Overcoming reprogramming resistance of Fanconi anemia cells
    Lars U W Müller
    Division of Pediatric Hematology Oncology, Children s Hospital Boston, and Dana Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 119:5449-57. 2012
    ..These data define the role of the FA pathway in reprogramming and provide a strategy for future translational applications of patient-specific FA iPSCs...